Date 2021-05-05
Authors Nicolas Raymond Summary Acute lymphoblastic leukemia (ALL) accounts for nearly one-third of all pediatric cancers in Canada each year. Although current treatments achieve a 5-year survival rate of 90%, we observe that more than 65% of survivors develop long-term adverse effects including dyslipidemia, hypertension and osteoporosis.
